First-line treatment in open-angle glaucoma: An update

Expert Review of Ophthalmology

Volumn 8, Issue 6, 2013, Pages 587-594

  Turner, Suzanne A ^a   McNaught, Andrew I ^a  

^a CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

Author keywords

Alpha agonist; ALT; Beta blocker; Carbonic anhydrase inhibitor; Medical treatment; Open angle glaucoma; Prostaglandin; SLT; Trabeculectomy; Trabeculoplasty

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; MIOTIC AGENT; PROSTAGLANDIN; TIMOLOL; TRAVOPROST;

BLINDNESS; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HYPEREMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; HUMAN; INTRAOCULAR PRESSURE; LONG TERM CARE; LOW LEVEL LASER THERAPY; OPEN ANGLE GLAUCOMA; OPTIC NERVE ATROPHY; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; TRABECULECTOMY; TRABECULOPLASTY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; VISUAL FIELD;

EID: 84888122327     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/17469899.2013.855608     Document Type: Review

References (56)

1. Gordon MO, Beiser JA, Brandt JD et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120(6), 714-720, discuss 829-830 (2002).
2. Gestel AV, Webers CA, Beckers HJ, Peeters A, Severens JL, Schouten JS. Ocular hypertension and the risk of blindness. J. Glaucoma. (2013) (Epub ahead of print).
3. King AJ, Reddy A, Thompson JR, Rosenthal AR. The rates of blindness and of partial sight registration in glaucoma patients. Eye 14(Pt 4), 613-619 (2000).
4. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch. Ophthalmol. 121(1), 48-56 (2003).
5. Musch DC, Gillespie BW, Niziol LM, Lichter PR, Varma R; CIGTS Study Group. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 118(9), 1766-1773 (2011).
6. Zimmerman TJ. Timolol maleate-a new glaucoma medication? Invest. Ophthalmol. Vis. Sci. 16(8), 687-688 (1977).
7. Cohen JS, Gross RL, Cheetham JK, Van Den burgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv. Ophthalmol. 49(Suppl. 1), S45-S52 (2004).
8. Watson PG, Barnett MF, Parker V, Haybittle J. A 7-year prospective comparative study of three topical beta-blockers in the management of primary open angle glaucoma. Br. J. Ophthalmol. 85(8), 962-968 (2001).
9. Bali SJ, Parmar T, Arora V, Ichhpujani P, Sagar R, Dada T. Evaluation of major depressive disorder in patients receiving chronic treatment with topical timolol. Ophthalmologica 226(3), 157-160 (2011).
10. Campbell RJ, Trope GE, Rachmiel R, Buys YM. Glaucoma laser and surgical procedure rates in Canada: a long-term profile. Can. J. Ophthalmol. 43(4), 449-453 (2008).
11. Keenan TD, Wotton CJ, Goldacre MJ. Recent trends in the rate of trabeculectomy in England. Eye (Lond.) 25 (9), 1243-1245 (2011).
12. Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J. Glaucoma. 18(9), 652 (2009).
13. Faridi UA, Saleh TA, Ewings P et al. Comparative study of three prostaglandin analogues in the treatment of newly diagnosed cases of ocular hypertension, open-angle and normal tension glaucoma. Clin. Exp. Ophthalmol. 38(7), 678-682 (2010).
14. Zhang WY, Po AL, Dua HS, Azuara-Blanco A. Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension. Br. J. Ophthalmol. 85(8), 983-990 (2001).
15. Uusitalo H, Pillunat LE, Ropo A, Phase III investigators. Acta Ophthalmol. 88(1), 12-19 (2010).
16. Alm A, Schoenfelder J, McDermott J. A 5-year, multicentre, open-label, safety study of adjunctive latanoprost therapy for glaucoma. Arch. Ophth. 122(7), 957-965 (2004).
17. Vass C, Hirn C, Sycha T, Findl O, Bauer P, Schmetterer L. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database Syst. Rev. (4), CD003167 (2007).
18. Garway-Heath DF, Lascaratos G, Bunce C, Crabb DP, Russell RA, Shah A; United Kingdom Glaucoma Treatment Study Investigators. The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology. Ophthalmology 120(1), 68-76 (2013).
19. Hodge WG, Lachaine J, Steffensen I et al. The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review. Br. J. Ophthalmol. 92(1), 7-12 (2008).
20. Henderer JD, Wilson RP, Moster MR, Myers J, Schmidt C, Fontanarosa J, Steinmann WC. Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30. mm Hg. J. Glaucoma. 14(4), 267-270 (2005).
21. Pajic B, Pajic-Eggspuehler B, Häfliger IO. Comparison of the effects of dorzolamide/timolol and latanoprost/timolol fixed combinations upon intraocular pressure and progression of visual field damage in primary open-angle glaucoma. Curr. Med. Res. Opin. 26(9), 2213-2219 (2010).
22. Mikelberg FS, Etminan M. Combination therapy as initial treatment in glaucoma and suspected glaucoma. Can. J. Ophthalmol. 47(3), 240-242 (2012).
23. Heijl A, Peters D, Leske MC, Bengtsson B. Effects of argon laser trabeculoplasty in the EMGT. AJO 152(5), 642-648 (2011).
24. Odberg T, Sandvik L. The medium and long-term efficacy of primary argon laser trabeculoplasty in avoiding topical medication in open angle glaucoma. Acta Ophthalmol. Scand. 77(2), 176-810 (1999).
25. Moulin F, Haut J. Argon laser trabeculoplasty: a 10-year follow-up. Ophthalmologica 207(4), 196-201 (1993).
26. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT): Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology 97, 1403-1413 (1990).
27. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7; results. Am. J. Ophthalmol. 120, 718-731 (1995).
28. Melamed S, Ben Simon GJ, Levkovitz-Verbin H. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma: a prospective, non-randomised pilot study. Arch. Ophthalmol. 121, 957-960 (2003).
29. Nagar M, Ogunyomade A, O'Brart DP et al. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br. J. Ophthalmol. 89, 1413-1417 (2005).
30. McIlraith I, Strasfeld M, Coley G, Hutnik CML. Selective laser trabeculoplasty as initial and adjunctive treatment for open-angle glaucoma. J. Glaucoma 15, 124-130 (2006).
31. Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, Marcellino G; SLT/Med Study Group. Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J. Glaucoma. 21(7), 460-468 (2012).
32. Liu Y, Birt CM. Argon versus selective laser trabeculoplasty in younger patients: 2-year results. J. Glaucoma. 21(2), 112-115 (2012).
33. Ayala M, Chen E. Long-term outcomes of SLT treatment. Open Ophthalmol. J. 5, 32-34 (2011).
34. Van de Veire S, Zeyen T, Stalmans I. Argon versus selective laser trabeculoplasty. Bull. Soc. Belge. Ophthalmol. (299), 5-10 (2006).
35. Harasymowycz PJ, Papamatheakis DG, Latina M, De Leon M, Lesk MR, Damji KF. Selective laser trabeculoplasty (SLT) complicated by intraocular pressure elevation in eyes with heavily pigmented trabecular meshworks. Am. J. Ophthalmol. 139(6), 1110-1113 (2005).
36. Wimmer I, Welge-Luessen U, Picht G, Grehn F. Influence of ALT on TGF beta concentration and bleb scarring following trabeculectomy. Graefes. Arch. Clin. Exp. Ophthalmol. 241(8), 631-636 (2003).
37. Fea AM, Bosone A, Rolle T, Brogliatti B, Grignolo FM. Micropulse diode laser trabeculoplasty (MDLT): a Phase II clinical study with 12. months follow-up. Clin. Ophthalmol. 2(2), 247-252 (2008).
38. Smith RJ. Medical versus surgical therapy in glaucoma simplex. Br. J. Ophthalmol. 56(3), 277-283 (1972).
39. Jay JL, Murray SB. Early trabeculectomy versus conventional management in primary open angle glaucoma. Br. J. Ophthalmol. 72(12), 881-889 (1988).
40. Burr J, Azuara-Blanco A, Avenell A, Tulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst. Rev. 9, CD004399 (2012).
41. Patel I, de Klerk TA, Au L. Manchester iStent study: early results from a prospective UK case series. Clin. Exp. Ophthalmol. doi: 10.1111/ceo.12098 (2013) (Epub ahead of print).
42. Shingleton BJ, Gamell LS, O' Donoghue MW, Baylus SL, King R. Long-term changes in intra-ocular pressure after clear corneal phacoemulsification: normal patients versus glaucoma suspects and glaucoma patients. J. Cataract. Refract. Surg. 25, 885-890 (1999).
43. Singleton BJ, Pasternak JJ, Hung JW, O'Donoghue MW. Three and five year changes in intraocular pressures after clear corneal phacoemulsification in open angle glaucoma patients, glaucoma suspects, and normal patients. J. Glaucoma. 15, 494-498 (2006).
44. Kim DD, Doyle JW, Smith MF. Intraocular pressure reduction following phacoemulsification cataract extraction with posterior chamber lens implantation in glaucoma patients. Ophthalmic. Surg. Lasers 30, 37-40 (1999).
45. Ahuja Y, Ma Khin Pyi S, Malihi M, Hodge DO, Sit AJ. Clinical results of Ab interno trabeculotomy using the trabectome for open-angle glaucoma. Am. J. Ophthalmol. pii: S0002-9394(13)00388-7, doi:10.1016/j.ajo.2013.06.001 (2013) (Epub ahead of print).
46. The European Glaucoma Society. Dogma srl, Savona, Italy, 81-82 (1998).
47. Stein JD, Kim DD, Peck WW, Giannetti SM, Hutton DW. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch. Ophthalmol. 130, 497-505 (2012).
48. Bovell AM, Damji KF, Hodge WG, Rock WJ, Buhrmann RR, Pan YI. Long-term effects on the lowering of IOP: SLT or ALT? Can. J. Ophthalmol. 46(5), 408-413 (2011).
49. Coyle D, Drummond M. The economic burden of glaucoma in the UK. Pharmacol. Econ. 7(6), 484-489 (1995).
50. Kobelt-Nguyen G, Gerdtham U-G, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: A retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J. Glaucoma. 7, 95-104 (1998).
51. Jonsson B, Kreiglstein G (Eds). Chapters 13. and 20. In: Primary Open-Angle Glaucoma. Differences in International Treatment Patterns and Costs. Isis Medical Media Ltd, Oxford, UK (1998).
52. Thelen U, Schnober D, Schölzel S et al. Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany. Int. J. Ophthalmol. 6(2), 155-159 (2013).
53. Van Gestel A, Webers CA, Severens JL et al. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol. 90(1), 20-31 (2012).
54. Texler-Richard B, Buchholz P, Bron A, Renard JP, Rouland JF, Nordmann JP. Treatment of glaucoma in clinical practice: four-year results from a patient registry in France. J. Glaucoma. 19(3), 199-206 (2010).
55. Uusitalo H, Niño J, Tahvanainen K et al. Efficacy and systemic side effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophtalmologica. Scand. 83(6), 723-728 (2005).
56. Lichter PR, Musch DC, Gillespie BW et al.; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 108(11), 1943-1953 (2001).